H.C. Wainwright issued a report on Proteon Therapeutics (NASDAQ:PRTO), raising its target price to $18.00 today
- Updated: September 21, 2016
Yesterday Proteon Therapeutics (NASDAQ:PRTO) traded 3.80% higher at $8.75. The company’s 50-day moving average is $9.10 and its 200-day moving average is $7.91. The last stock close price is up 10.56% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 8,536 shares of the stock were exchanged, down from an average trading volume of 31,439
Proteon Therapeutics (NASDAQ:PRTO) had its target price raised to $18.00 by H.C. Wainwright in a report released 09/22/2016. The new target price indicates a possible upside of 1.06% based on the company's last stock close price.
Previously on 4/14/2016, Robert W. Baird reported about Proteon Therapeutics (NASDAQ:PRTO) raised the target price from $0.00 to $20.00. At the time, this indicated a possible upside of 1.39%.
See Chart Below
Proteon Therapeutics has a 52 week low of $4.90 and a 52 week high of $17.76 The company’s market cap is currently $0.
Also covering Proteon Therapeutics's target, a total of 5 firms have issued a report on Proteon Therapeutics. The 12-month price target is $21.40 with two analysts rating the company a strong buy, 2 equity analysts rating the company a buy, zero brokers rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 equity analysts rating the company a sell.
Brief Synopsis About Proteon Therapeutics (NASDAQ:PRTO)
Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company's product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.